
Published: 11 months ago
Size: 35.3MB
In this activity, experts in the treatment of multiple sclerosis present the most current safety data associated with the use of broad-spectrum immunomodulatory/immunosuppressive agents and monoclonal antibodies in multiple sclerosis. In addition, the investigational status of oral therapies in MS is clarified.
unknown filetype: pdf
Published: 11 months ago
Size: 233.8KB
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.

Published: 12 months ago
Size: 23.8MB
In this activity, experts in the treatment of multiple sclerosis discuss data presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2007) concerning the use of the monoclonal antibodies natalizumab, rituximab, daclizumab, and alemtuzumab in this disorder.
unknown filetype: pdf
Published: 12 months ago
Size: 219.0KB
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.

Published: 1 year ago
Size: 20.6MB
In this activity, an expert in the management of multiple sclerosis (MS) discusses data supporting the early use of interferon-beta and describes the current clinical development of targeted agents and oral compounds in this condition.